Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Lazertinib + Amivantamab for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing the combination of two drugs, lazertinib and amivantamab, to treat EGFR-mutated non-small cell lung cancer. The first part of the trial is to see if the recommended doses of both drugs are tolerable when used together. The second part is to see if the combination of the two drugs is effective at treating the cancer.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.